Published in Tubercle on March 01, 1979
Cetyl-pyridinium chloride is useful for isolation of Mycobacterium tuberculosis from sputa subjected to long-term storage. J Clin Microbiol (2005) 1.82
Comparison of sodium carbonate, cetyl-pyridinium chloride, and sodium borate for preservation of sputa for culture of Mycobacterium tuberculosis. J Clin Microbiol (2003) 1.36
Efficacy of chemical dosing methods for isolating nontuberculous mycobacteria from water supplies of dialysis centers. Appl Environ Microbiol (1988) 1.33
Rate of recovery of Mycobacterium tuberculosis from frozen acid-fast-bacillus smear-positive sputum samples subjected to long-term storage in Northwest Ethiopia. J Clin Microbiol (2011) 1.12
Processing sputum specimens in a refrigerated centrifuge does not increase the rate of isolation of Mycobacterium tuberculosis. J Clin Microbiol (2003) 0.78
Evaluation of Mycobacterium tuberculosis viability in OMNIgene-SPUTUM reagent upon multi-day transport at ambient temperature. BMC Infect Dis (2017) 0.75
Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med (2001) 6.05
Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis. Antimicrob Agents Chemother (1972) 4.64
Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol (1970) 3.65
The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy. Nat Genet (2000) 3.35
Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for exclusion of antimicrobial agents? Antimicrob Agents Chemother (1981) 3.16
Mycobacterium simiae and Mycobacterium avium-M. intracellulare mixed infection in acquired immune deficiency syndrome. J Clin Microbiol (1987) 3.01
Fourth report of the cooperative, open-ended study of slowly growing mycobacteria by the International Working Group on Mycobacterial Taxonomy. Int J Syst Bacteriol (1991) 2.31
Drug susceptibility testing in tuberculosis: a comparison of the proportion methods using Lowenstein-Jensen, Middlebrook 7H10 and 7H11 agar media and a radiometric method. Res Microbiol (1990) 2.25
Genetic diversity of Mycobacterium africanum clinical isolates based on IS6110-restriction fragment length polymorphism analysis, spoligotyping, and variable number of tandem DNA repeats. J Clin Microbiol (2001) 2.22
Use of cetylpyridinium chloride and sodium chloride for the decontamination of sputum specimens that are transported to the laboratory for the isolation of Mycobacterium tuberculosis. J Clin Microbiol (1975) 2.21
Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients. Brain (2009) 1.91
[Comparative study of the Ziehl-Neelsen and fluorescent microscopy methods of staining tubercle bacilli of excised pulmonary tissue]. Arch Inst Pasteur Alger (1971) 1.73
Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis. Antimicrob Agents Chemother (1990) 1.72
Is second-line anti-tuberculosis drug susceptibility testing reliable? Int J Tuberc Lung Dis (2004) 1.67
Basis for lack of drug susceptibility of atypical mycobacteria. Rev Infect Dis (1982) 1.63
Mycolic acid analysis for clinical identification of Mycobacterium avium and related mycobacteria. J Clin Microbiol (1986) 1.61
Identification of Mycobacterium fortuitum and Mycobacterium chelonei. J Clin Microbiol (1983) 1.57
Effect of temperature on the rate of the transparent to opaque colony type transition in Mycobacterium avium. Antimicrob Agents Chemother (1976) 1.56
An epidemic of tuberculosis with a high rate of tuberculin anergy among a population previously unexposed to tuberculosis, the Yanomami Indians of the Brazilian Amazon. Proc Natl Acad Sci U S A (1997) 1.55
Mechanisms of pathogenicity in mycobacteria. Biochimie (1988) 1.45
Some observations on the genetics of isoniazid resistance in the tubercle bacilli. Am Rev Respir Dis (1971) 1.45
Autosomal-recessive forms of demyelinating Charcot-Marie-Tooth disease. Neuromolecular Med (2006) 1.42
Structure of the cell envelope of Mycobacterium avium. Zentralbl Bakteriol Mikrobiol Hyg A (1987) 1.41
Restriction endonuclease mapping and cloning of Mycobacterium fortuitum var. fortuitum plasmid pAL5000. Ann Inst Pasteur Microbiol (1986) 1.38
Response of Mycobacteria to ultraviolet light radiation. Am Rev Respir Dis (1973) 1.36
beta-Glucosidase activity in mycobacteria. J Clin Microbiol (1977) 1.32
Recent studies on mycobacterial differentiation by means of pyrolysis-gas-liquid chromatography. Am Rev Respir Dis (1971) 1.30
Spine deformities in Charcot-Marie-Tooth 4C caused by SH3TC2 gene mutations. Neurology (2006) 1.30
Acridine orange as a fluorescent counterstain with the auramine acid-fast stain. Tubercle (1971) 1.22
Susceptibility of mycobacterial D-alanyl-D-alanine synthetase to D-cycloserine. Am Rev Respir Dis (1969) 1.21
[Evaluation of urease and beta-glucosidase activity for the practical identification of mycobacteria (author's transl)]. Ann Microbiol (Paris) (1979) 1.17
Serological specificity of Mycobacterium tuberculosis glycolipids. Acta Leprol (1989) 1.16
Differential identification of Mycobacterium fortuitum and Mycobacterium chelonei. J Clin Microbiol (1981) 1.15
Preliminary observations on the occurrence of a streptomycin R-factor in Mycobacterium smegmatis ATCC 607. Tubercle (1972) 1.12
Identification of seven novel mutations in the GAN gene. Hum Mutat (2003) 1.07
Evaluation of a novel 2,3-diacyl-trehalose-2'-sulphate (SL-IV) antigen for case finding and diagnosis of leprosy and tuberculosis. Res Microbiol (1991) 1.07
Antibacterial action of amphipathic derivatives of isoniazid against the Mycobacterium avium complex. Zentralbl Bakteriol Mikrobiol Hyg A (1988) 1.06
Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs. Int J Tuberc Lung Dis (2012) 1.05
High prevalence of methicillin-resistant Staphylococcus aureus clone ST80-IV in hospital and community settings in Algiers. Clin Microbiol Infect (2011) 1.04
Glycolipids of recent clinical isolates of Mycobacterium tuberculosis: chemical characterization and immunoreactivity. J Gen Microbiol (1989) 1.04
Mycobacteriophage D29 contains an integration system similar to that of the temperate mycobacteriophage L5. Microbiology (1997) 1.04
Susceptibility of mycobacteria to rifampin. Antimicrob Agents Chemother (1972) 1.04
Conjugative transfer of a shuttle plasmid from Escherichia coli to Mycobacterium smegmatis [corrected]. FEMS Microbiol Lett (1990) 1.03
Surveillance of drug resistance for tuberculosis control: why and how? Tuber Lung Dis (1995) 1.03
Classification and identification of Mycobacterium africanum by pyrolysis mass spectrometry. J Gen Microbiol (1983) 1.02
Preparation of a stable mycobacterial tween hydrolysis test substrate. Appl Microbiol (1973) 1.01
Resistance to D-cycloserine in the tubercle bacilli: mutation rate and transport of alanine in parental cells and drug-resistant mutants. Appl Microbiol (1971) 1.00
A national survey of human Mycobacterium bovis infection in France. Network of Microbiology Laboratories in France. Int J Tuberc Lung Dis (1999) 1.00
Selective inhibition of the Mycobacterium tuberculosis complex by p-nitro-alpha-acetylamino-beta-hydroxypropio phenone (NAP) and p-nitrobenzoic acid (PNB) used in 7H11 agar medium. Res Microbiol (1990) 0.99
Activity of five fluoroquinolones against Mycobacterium avium-intracellulare complex and M. xenopi. Ann Inst Pasteur Microbiol (1988) 0.99
[Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis. Groupe de Travail sur la Chimiothérapie de la Tuberculose]. Tuber Lung Dis (1995) 0.98
Ultraviolet light inactivation and photoreactivation in the mycobacteria. Infect Immun (1971) 0.98
Reagent-impregnated paper strip for detection of metabolic products of isoniazid in urine. Am Rev Respir Dis (1972) 0.98
Intrinsic resistance of Mycobacterium tuberculosis to clarithromycin is effectively reversed by subinhibitory concentrations of cell wall inhibitors. J Antimicrob Chemother (2000) 0.97
Inhibition by fifampin of mycobacteriophage D29 replication in its drug-resistant host, Mycobacterium smergmatis ATCC 607. Am Rev Respir Dis (1971) 0.97
Ability of smooth and rough variants of Mycobacterium avium and M. intracellulare to multiply and survive intracellularly: role of C-mycosides. Zentralbl Bakteriol Mikrobiol Hyg A (1989) 0.96
Evaluation of rapid tests for the identification of mycobacteria. J Med Microbiol (1982) 0.96
Ultrastructural and chemical studies on wall-deficient forms, spheroplasts and membrane vesicles from Mycobacterium aurum. J Gen Microbiol (1981) 0.96
Action of colistin (polymyxin E) on the lytic cycle of the mycobacteriophage D29 in Mycobacterium tuberculosis. Zentralbl Bakteriol Mikrobiol Hyg A (1986) 0.95
Macrophage interaction with mycobacteria including M. leprae. Acta Leprol (1985) 0.95
The occurrence of lipids in Mycobacteriophage D29 propagated in Mycobacterium smegmatis ATCC 607. Am Rev Respir Dis (1970) 0.92
Preliminary evaluation of a Mycobacterium tuberculosis phenolglycolipid antigen in the serologic diagnosis of tuberculosis. Ann Inst Pasteur Microbiol (1988) 0.92
Comparative intracellular growth of difficult-to-grow and other mycobacteria in a macrophage cell line. Acta Leprol (1989) 0.92
The phenotypic manifestations of autosomal recessive axonal Charcot-Marie-Tooth due to a mutation in Lamin A/C gene. Neuromuscul Disord (2003) 0.91
Prevalence and characterization of extended-spectrum beta-lactamases in Klebsiella pneumoniae in Algiers hospitals (Algeria). Pathol Biol (Paris) (2008) 0.91
Charcot-Marie-Tooth 2-like presentation of an Algerian family with giant axonal neuropathy. Neuromuscul Disord (2000) 0.90
Mutations affecting pigment synthesis in Mycobacterium aurum. J Gen Microbiol (1979) 0.90
Growth and cell division of Mycobacterium avium. J Gen Microbiol (1981) 0.89
Regulatory mechanisms in the mycobacteria. Ann Microbiol (Paris) (1978) 0.89
Mutations in the glucocerebrosidase gene confer a risk for Parkinson disease in North Africa. Neurology (2011) 0.89
Pyrazinamide is not effective against intracellularly growing Mycobacterium tuberculosis. Antimicrob Agents Chemother (1988) 0.88
Reduction of potassium tellurite and ATP content in Mycobacterium leprae. Ann Microbiol (Paris) (1982) 0.88
Differentiation of Mycobacterium thermoresistibile from Mycobacterium phlei and other rapidly growing mycobacteria. Ann Inst Pasteur Microbiol (1988) 0.87
Mode of action of antituberculous drugs and mechanisms of drug resistance in Mycobacterium tuberculosis. Res Microbiol (1993) 0.87
[Role of Mycobacterium tuberculosis in bovine tuberculosis]. Arch Inst Pasteur Alger (1982) 0.87
The CHRNE 1293insG founder mutation is a frequent cause of congenital myasthenia in North Africa. Neurology (2008) 0.87
Antigenicity and specificity of selected glycolipid fractions from Mycobacterium tuberculosis. Res Microbiol (1989) 0.87
Biogenesis of beta-carotene in Mycobacterium kansasii. J Bacteriol (1974) 0.87
[Controlled study comparing 3 daily chemotherapy regimens for six months in pulmonary tuberculosis in routine practice in Algiers. Results at 30 months]. Rev Mal Respir (1985) 0.86
Low disease risk in relatives of north african lrrk2 Parkinson disease patients. Neurology (2010) 0.86
A new insight into the mycobacterial cell envelope architecture by the localization of antigens in ultrathin sections. Zentralbl Bakteriol (1991) 0.86
[Mycobacterium kansasii: drinking water contaminant of a hospital]. Rev Epidemiol Sante Publique (1983) 0.86
Prevalence of primary and acquired resistance of Mycobacterium tuberculosis to antituberculosis drugs in Benin after 12 years of short-course chemotherapy. Int J Tuberc Lung Dis (1999) 0.86
DOT-ELISA for detection of phenolic glycolipid PGL-Tb1 and diacyl-trehalose antigens of Mycobacterium tuberculosis. Res Microbiol (1992) 0.85
[A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment]. Rev Mal Respir (1990) 0.85
Use of two methods of analysis to estimate the annual rate of tuberculosis infection in Southern Algeria. Tuber Lung Dis (1996) 0.85
Isolation and characterization of uridine diphosphate-N-glycolylmuramyl-L-alanyl-gamma-D-glutamyl-meso-alpha,alpha'-diaminopimelic acid from Mycobacterium tuberculosis. Biochem Biophys Res Commun (1970) 0.85
Effect of O-carbamyl-D-serine on the growth of mycobacterium tuberculosis. Am Rev Respir Dis (1970) 0.85
Specific surface antigens of SmT variants of Mycobacterium avium. Infect Immun (1984) 0.85
Molecular diagnosis of known recessive ataxias by homozygosity mapping with SNP arrays. J Neurol (2010) 0.85
Restoration of mycolate synthetase activity in Mycobacterium tuberculosis exposed to isoniazid. Am Rev Respir Dis (1974) 0.84
Further studies on colistin (polymyxin E)-induced cell leakage in mycobacteria: Mg++ efflux in Mycobacterium avium and its effects on drug-susceptibility. Zentralbl Bakteriol Mikrobiol Hyg A (1988) 0.83
Antimicrobial resistance of respiratory pathogens in North African countries. J Chemother (2009) 0.83
Effects of antituberculosis and antileprosy drugs on mycobacteriophage D29 growth. Antimicrob Agents Chemother (1980) 0.83
Antibacterial action of colistin (polymyxin E) against Mycobacterium aurum. Antimicrob Agents Chemother (1985) 0.83
Adsorption of mycobacteriophage D29 on Mycobacterium leprae. Ann Microbiol (Paris) (1978) 0.82
Action of antituberculous and beta-lactam drugs (including imipenem) against extra- and intra-cellularly growing Mycobacterium avium-intracellulare. Ann Inst Pasteur Microbiol (1988) 0.82
Abortive infection of Mycobacterium leprae by the mycobacteriophage D29. Int J Lepr Other Mycobact Dis (1984) 0.82